CLCS (Cell Source) Cyclically Adjusted PB Ratio: (As of Jun. 30, 2026)


CLCS Cell Source Inc CLCS
35 GF Score
Price $0.81
View Full Analysis

What is Cell Source Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cell Source  (OTCPK:CLCS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cell Source Cyclically Adjusted PB Ratio Related Terms


Cell Source Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Cell Source's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source Cyclically Adjusted PB Ratio Chart

Cell Source Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cell Source Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CLCS vs EDSA, CTXR, ASBP: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Cell Source's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cell Source Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cell Source's Cyclically Adjusted PB Ratio falls into.


CLCS
35GF Score
Cell Source Inc CLCS
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cell Source's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Cell Source's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.412/315.6050*315.6050
=-0.412

Current CPI (Dec. 2024) = 315.6050.

Cell Source Quarterly Data

Book Value per Share CPI Adj_Book
201503 -0.184 236.119 -0.246
201506 -0.208 238.638 -0.275
201509 -0.234 237.945 -0.310
201512 -0.241 236.525 -0.322
201603 -0.274 238.132 -0.363
201606 -0.302 241.018 -0.395
201609 -0.320 241.428 -0.418
201612 -0.256 241.432 -0.335
201703 -0.225 243.801 -0.291
201706 -0.213 244.955 -0.274
201709 -0.225 246.819 -0.288
201712 -0.180 246.524 -0.230
201803 -0.210 249.554 -0.266
201806 -0.229 251.989 -0.287
201809 -0.235 252.439 -0.294
201812 -0.189 251.233 -0.237
201903 -0.196 254.202 -0.243
201906 -0.195 256.143 -0.240
201909 -0.223 256.759 -0.274
201912 -0.212 256.974 -0.260
202003 -0.229 258.115 -0.280
202006 -0.220 257.797 -0.269
202009 -0.234 260.280 -0.284
202012 -0.244 260.474 -0.296
202103 -0.277 264.877 -0.330
202106 -0.301 271.696 -0.350
202109 -0.303 274.310 -0.349
202112 -0.286 278.802 -0.324
202203 -0.290 287.504 -0.318
202206 -0.306 296.311 -0.326
202209 -0.339 296.808 -0.360
202212 -0.350 296.797 -0.372
202303 -0.382 301.836 -0.399
202306 -0.392 305.109 -0.405
202309 -0.416 307.789 -0.427
202312 -0.392 306.746 -0.403
202403 -0.408 312.332 -0.412
202406 -0.413 314.175 -0.415
202409 -0.438 315.301 -0.438
202412 -0.412 315.605 -0.412

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.81
Price